Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 13 of the 52 sources its claims cite were checked for support.

Management of Treatment-Resistant Panic Disorder

Open access
Perna, Giampaolo, Caldirola, Daniela · 2017 · Current Treatment Options in Psychiatry

Abstract

Purpose of Review: Purpose of Review Management of treatment-resistant (TR) panic disorder (PD) is an unresolved issue. In this paper, we provide a brief summary of previous findings, an updated (2015–2017) systematic review of pharmacological/non-pharmacological studies, and our personal perspective on this topic. Recent Findings: Recent Findings We found a very limited number of recent findings. Quetiapine extended-release augmentation has not been found to be beneficial, in comparison to placebo, in non-responders to previously recommended pharmacotherapy. In non-responders to cognitive behavioral therapy (CBT), switching to paroxetine/citalopram has been found to be more effective than continuing CBT. Acceptance and commitment therapy (ACT) has shown some improvement in patients’ resistance to previous psychological/pharmacological interventions compared with a waiting-list condition. Summary: Summary Previous and recent findings regarding the treatment of TR PD suffer from several methodological limitations. Available studies provide insufficient evidence to support the use of medications alternative to the recommended medications; the efficacy of ACT needs confirmation with more rigorous methodology. Prolonged pharmacotherapy may produce significant improvement in patients with unsatisfactory response to short-term pharmacotherapy, while switching to pharmacotherapy may help non-responders to CBT. We discuss our personal perspective on the definition of “treatment resistance” as it relates to PD and provide personalized intervention strategies to increase favorable clinical outcomes based on our clinical expertise and review of experimental studies on the pathophysiology of PD. © 2017, The Author(s).

Overview

CoChat Summary

## TL;DR

This paper argues that treatment-resistant panic disorder (TRPD) remains poorly defined and poorly studied, and that current evidence is too limited to support alternative medications beyond recommended treatments. Its updated 2015–2017 review found only 3 eligible studies, with mixed results: quetiapine XR did not beat placebo, switching from CBT to SSRIs helped non-responders, and ACT showed some benefit but needs stronger confirmation.

## Key findings

  • The authors found a very limited evidence base: from 290 records, only 3 studies met inclusion criteria in the updated review.
  • In a small 8-week RCT of adjunctive quetiapine XR vs placebo in SSRI/SNRI-resistant patients with PD, symptoms improved in the whole sample, but there were no significant differences between quetiapine XR and placebo on primary or secondary outcomes.
  • In a 3-month randomized controlled trial of patients who did not respond to 12 individual CBT sessions, switching to paroxetine or citalopram led to significantly lower panic symptoms than continuing CBT.
  • In a 4-week waiting-list controlled trial, ACT improved panic-phobic symptoms, global illness severity, general anxiety/depressive symptoms, and fear of bodily sensations, but not agoraphobia, anxiety sensitivity, or agoraphobic cognitions.

## Methods

  • The paper combined a narrative summary of prior work with an updated systematic review conducted according to PRISMA.
  • The search covered PubMed, PsycINFO, and Embase for English-language peer-reviewed studies from January 1, 2015 to July 1, 2017; 290 records were identified and 3 studies were included.
  • Included studies had to involve adults (≥18 years) with a primary diagnosis of TRPD, use pharmacological and/or non-pharmacological interventions, and report validated psychometric outcomes; case reports, reviews, editorials, and similar items were excluded.

## Limitations

  • The paper states that the evidence suffers from several methodological limitations, including limited sample size, heterogeneous criteria for treatment resistance and outcome measures, and insufficient use of psychometric tools that separately assess panic symptoms, anticipatory anxiety, and phobic avoidance.
  • The authors note that the ACT study had a small sample size, no active therapy control, and no information about concomitant medications; the quetiapine XR trial also had a small sample and a mixed/unstandardized definition of SSRI/SNRI resistance.
  • Evident from the text: the review included only 3 studies, all within a narrow 2015–2017 window, so the evidence base is very small and may not support broad conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40501-017-0128-7

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA flow diagram of the study selection process.
Fig. 1 PRISMA flow diagram of the study selection process.CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 18 Not checked · 13 Own results and interpretations

20 more claims · 1 with their cited sources checked

Create a free account to see all 44 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 15
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 69 references

Cited by

See all 36

Metadata

Authors
Perna, G., & Caldirola, D.
Affiliations
  • Maastricht University (NL)
  • Hermanas Hospitalarias del Sagrado Corazón de Jesús (IT)
Corresponding author
Perna, Giampaolo
Venue
Current Treatment Options in Psychiatry
Published
2017-10-24
Volume
4
Issue
4
Pages
371-386
ISSN
2196-3061 (ISSN-L)
OpenAlex
W2766812746
Cited by
36
References
69
Citations by year
2026: 3 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 3 · 2021: 8 · 2020: 1 · 2019: 3 · 2018: 5
FWCI
0.39
Type
journal article
Language
en
Open access
Locations
  • Current Treatment Options in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
Funders
Maastricht University
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
panic disorder, cognitive behavioral therapy, paroxetine, citalopram, acceptance and commitment therapy, pharmacotherapy, psychological intervention, personalized treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Treatment-Resistant Panic Disorder. https://app.cochat.ai/papers/10.1007/s40501-017-0128-7
The paper
Perna, G., & Caldirola, D. (2017). Management of Treatment-Resistant Panic Disorder. Current Treatment Options in Psychiatry. https://doi.org/10.1007/s40501-017-0128-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.